We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00078117
First Posted: February 20, 2004
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.

Condition Intervention Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Opiate abstinence

Estimated Enrollment: 516
Study Start Date: June 2003
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females are not pregnant or lactating
  • Subjects meet DSM-IV criteria for opiate dependence, are medically and psychiatrically stable, and do not have a current history of benzodiazepine dependence abuse, dependence, or treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00078117


Locations
United States, Colorado
Addiction Research & Treatment Services (ARTS)
Denver, Colorado, United States, 80204
Denver Health & Hospitals Authority
Denver, Colorado, United States, 80204
United States, Connecticut
Hartford Dispensary
Hartford, Connecticut, United States, 06120
Connecticut Counseling Centers
Waterbury, Connecticut, United States, 06705
United States, New York
LI Jewish Health System
Glen Oaks, New York, United States, 11004
New York VA Medical Center
New York, New York, United States, 10010
United States, North Carolina
South Light-Wakeview Clinic
Raleigh, North Carolina, United States, 27610
Coastal Horizons Center, Inc.
Wilmington, North Carolina, United States, 28412
United States, Oregon
CODA
Portland, Oregon, United States, 97214
United States, Virginia
Norfolk CSB
Norfolk, Virginia, United States, 23505
United States, Washington
Providence Behavioral Health Services
Everett, Washington, United States, 98201
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Walter Ling, M.D. University of California, Los Angeles
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Walter Ling, M.D., University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00078117     History of Changes
Other Study ID Numbers: NIDA-CTN-0003-1
First Submitted: February 19, 2004
First Posted: February 20, 2004
Last Update Posted: January 12, 2017
Last Verified: April 2010

Keywords provided by National Institute on Drug Abuse (NIDA):
opiate dependence

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists